Your English writing platform
Discover LudwigExact(1)
First, the poor membrane permeability of siRNA limits cellular uptake.
Similar(59)
However, the broad therapeutic applications of siRNA are limited by major delivery problems.
Although the high degree of MCF7 cell death caused by TFIIS siRNA limited the amount of protein attainable, starting from large quantities of cells, we were able to perform a western analysis of TFIIS employing tubulin for normalization.
Furthermore, the costly and time-consuming synthesis and validation of designed siRNAs limit their use in large-scale studies.
The therapeutic utility of siRNAs is limited by the requirement for complex formulations to deliver them to tissues.
Since the systemic administration of siRNAs is limited by their capacity to attain the site of action, novel delivery systems are needed.
Small interfering RNA (siRNA) is a promising biological strategy for treatment of diverse diseases, but the therapeutic application of siRNA has been limited by its instability and poor cellular uptake efficiency.
In the present study, we evaluated the use of siRNA therapy to limit and prevent EHV-1 infection in vitro and in a murine model of EHV-1 infection.
The clinical utility of siRNA has been limited to its inherent properties; for example, naked siRNA is prone to degradation and has a shorter plasma half-life, rapid renal clearance, and limited permeability across cell membranes [ 17].
Since the study is highly dependent on the use of siRNA approaches, these questions limit the impact of the study.
Small interfering RNA (siRNA) as a promising anti-sense molecule can specifically silence inflammation related genes in ATCs, however, lack of safe and efficient siRNA delivery systems limits the application of siRNA as a therapeutic molecule in asthma.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com